Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 efficacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials

被引：0

作者：

Kokolakis, Georgios ^{[1
,2
,3
]}

Martorell, Antonio ^{[4
]}

Kerdel, Francisco ^{[5
]}

Bettoli, Vincenzo ^{[6
]}

Giamarellos-Bourboulis, Evangelos J. ^{[7
]}

Sinclair, Rodney ^{[8
]}

Kasparek, Torben ^{[9
]}

Li, Xianjun ^{[10
]}

Martinez, Angela Llobet ^{[9
]}

Uhlmann, Lorenz ^{[9
]}

Muscianisi, Elisa ^{[11
]}

机构：

[1] Charite Univ Med Berlin, Psoriasis Res & Treatment Ctr, Dept Dermatol Venereol & Allergol, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] Hosp Manises, Dept Dermatol, Valencia, Spain

[5] Florida Acad Ctr Res & Educ, Coral Gables, FL USA

[6] Azienda Osped Univ Ferrara, Dept Oncol & Specialist Med, OU Dermatol, Ferrara, Italy

[7] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med 4, Athens, Greece

[8] Sinclair Dermatol, Melbourne, Vic, Australia

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Pharmaceut, Shanghai, Peoples R China

[11] Novartis Pharmaceut, E Hanover, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

42981

引用

页码：AB85 / AB85

页数：1

共 50 条

[21] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study
Kimball, Alexa B.
Ackerman, Lindsay
Schlosser, Bethanee J.
Prajapati, Vimal H.
Fretzin, Scott
Takahashi, Hidetoshi
Zhan, Tianyu
Huang, Xiaohong
Camp, Heidi S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB42 - AB42
[22] Bimekizumab efficacy and impact on pain in moderate-to-severe hidradenitis suppurativa: results from BE HEARD I and II
Ingram, John R.
Orenstein, Lauren A., V
Shi, Vivian Y.
Lev-Tov, Hadar
Prens, Errol
Lambert, Jeremy
Rolleri, Robert
Kirby, Brian
Rashidghamat, Ellie
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I53 - I53
[23] Efficacy and safety of adalimumab for moderate to severe hidradenitis suppurativa: Results from the open-label phase of a 52-week phase II, randomized, study
Kimball, Alexa
Williams, David
Jemec, Gregor
Gu, Yihua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB50 - AB50
[24] Secukinumab in bio-experienced patients with moderate-to-severe hidradenitis suppurativa from a single center: an observational retrospective study
Tran, Thuy M.
Akpala, Christeebella O.
Tran, Tung S.
Davis, Mark Denis P.
Baum, Christian L.
Alavi, Afsaneh
Wetter, David A.
Nguyen, Giang H.
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024,
[25] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
Rui, Wenlong
Li, Xia
Zheng, Jie
Pan, Weili
Zheng, Min
Lu, Yan
Li, Fuqiu
Ding, Yangfeng
Zhang, Jianzhong
Li, Hongying
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
[26] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
Li Xia
Zheng Jie
Pan WeiLi
Zheng Min
Lu Yan
Li FuQiu
Ding YangFeng
Zhang JianZhong
Li HongYing
Rui WenLong
国际皮肤性病学杂志（英文）, 2022, 05 (04)
[27] Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomised placebo-controlled trial
Herra, L. Escudero
Jemec, G. B. E.
Gottlieb, A.
Forman, S.
Giamarellos-Bourboulis, E. J.
Reguiai, Z.
Gu, Y.
Okun, M. M.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 35
[28] Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3, randomized, placebo-controlled trial
Jemec, Gregor
Gottlieb, Alice
Forman, Seth
Giamarellos-Bourboulis, Evangelos
Reguiai, Ziad
Gu, Yihua
Okun, Martin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB45 - AB45
[29] Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials
Draelos, Zoe
Kempers, Steven
Helfrich, Yolanda
Meng, Xiangyi
Fox, Todd
Nyirady, Judit
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
[30] Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Kimball, Alexa B.
Jemec, Gregor B. E.
Sayed, Christopher J.
Kirby, Joslyn S.
Prens, Errol
Ingram, John R.
Garg, Amit
Gottlieb, Alice B.
Szepietowski, Jacek C.
Bechara, Falk G.
Giamarellos-Bourboulis, Evangelos J.
Fujita, Hideki
Rolleri, Robert
Joshi, Paulatsya
Dokhe, Pratiksha
Muller, Edward
Peterson, Luke
Madden, Cynthia
Bari, Muhammad
Zouboulis, Christos C.
LANCET, 2024, 403 (10443): : 2504 - 2519

← 1 2 3 4 5 →